Bruker (BRKR)
(Delayed Data from NSDQ)
$63.32 USD
-0.05 (-0.08%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $63.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$63.32 USD
-0.05 (-0.08%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $63.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
Smith & Nephew (SNN) Buys Brainlab, Braces Robotic Ecosystem
by Zacks Equity Research
The transaction by Smith & Nephew (SNN), besides the business purchase, comprises certain intangible assets and the orthopaedic Brainlab salesforce.
Titan Medical (TMDI) Shows Promise on Strategic Developments
by Zacks Equity Research
Titan Medical (TMDI) is putting in a good deal of effort to strengthen its position in the multi-billion dollar computer-assisted robotic surgical technologies market.
Varian (VAR) Set to Exhibit ProBeam Proton Therapy System
by Zacks Equity Research
Varian's (VAR) ProBeam exhibition is in sync with its strategy to expand reach within the cancer care market.
Walgreens' Weak Market Trends a Woe, Strategic Deals a Boon
by Zacks Equity Research
Walgreens Boots (WBA) is diligently trying to redress specific areas of operational weakness and enhancing its managerial skills for a better operating performance.
QIAGEN-DiaSorin Union to Enhance QuantFERON for Lyme Disease
by Zacks Equity Research
QIAGEN (QGEN) expects multi-site clinical validations for this new system during 2020 Lyme disease season.
Here's Why You Should Invest in Quest Diagnostics (DGX) Stock
by Zacks Equity Research
Quest Diagnostics (DGX) is boosting investors' optimism, courtesy of consistent positive results.
LHC Group Finalizes Joint Venture Agreement With AtlantiCare
by Zacks Equity Research
LHC Group's (LHCG) deal is in line with its current strategy of collaborating with JV partners to expand service capabilities in core markets.
Abbott (ABT) Grows on EPD Amid Rhythm Management Challenges
by Zacks Equity Research
We are optimistic about the steady growth trend in Abbott's (ABT) EPD and Medical Devices segments on an organic basis.
Here's Why You Should Invest in Omnicell (OMCL) Stock Now
by Zacks Equity Research
Omnicell (OMCL) is boosting investors' optimism, courtesy of consistent positive results.
Myriad Genetics' (MYGN) POLO Study Shows Positive Results
by Zacks Equity Research
Myriad Genetics' (MYGN) collaboration with AstraZeneca garners several regulatory go-aheads for BRACAnalysis CDx test.
Bruker (BRKR) Up 7.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Luminex xMAP Picked by EDP Biotech to Boost Cancer Diagnostics
by Zacks Equity Research
Management at Luminex (LMNX) expects to see robust demand for Luminex's xMAP technology in 2019.
Here's Why You Should Retain Bio-Rad (BIO) Stock For Now
by Zacks Equity Research
Bio-Rad (BIO) continues to witness high investor confidence on strength in the Life Sciences segment.
Medtronic Receives FDA Nod for SelectSite Catheter System
by Zacks Equity Research
The launch of the SelectSite catheter is in line with Medtronic's (MDT) goal to expand its cardiac care portfolio.
Masimo's Technologies to be Deployed to Boost Pediatric Care
by Zacks Equity Research
NuVision's centers are to be equipped with Masimo's (MASI) SET, Root with Radical-7, NomoLine Capnography and Patient SafetyNet technologies.
Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now
by Zacks Equity Research
IDEXX (IDXX) registers strong revenue growth on the back of CAG Diagnostics.
QIAGEN (QGEN) Launches PIK3CA Kit for Breast Cancer Patients
by Zacks Equity Research
QIAGEN's (QGEN) therascreen PIK3CA Kit is the first companion diagnostic test to have attained premarket approval from the FDA.
Here's Why You Should Retain NuVasive (NUVA) Stock for Now
by Zacks Equity Research
Investor confidence in the stock is high on NuVasive's (NUVA) sturdy spine business.
Here's Why You Should Hold on to Hill-Rom (HRC) Stock Now
by Zacks Equity Research
Investor confidence in the stock is high on Hill-Rom's (HRC) recent acquisition of Voalte.
Here's Why You Should Hold Varian Medical (VAR) Stock Now
by Zacks Equity Research
Varian Medical (VAR) raises revenue guidance for 2019 encourages.
Bruker (BRKR) Q1 Earnings Beat Estimates, Guidance Upbeat
by Zacks Equity Research
Bruker's (BRKR) current focus on product development through higher R&D investment stokes investors' positive sentiment around the stock.
Here's Why Momentum Investors Will Love Bruker (BRKR)
by Zacks Equity Research
Does Bruker (BRKR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Bruker (BRKR) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Bruker (BRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Looking for a Growth Stock? 3 Reasons Why Bruker (BRKR) is a Solid Choice
by Zacks Equity Research
Bruker (BRKR) could produce exceptional returns because of its solid growth attributes.
Bruker (BRKR) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 16.67% and 1.45%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?